BACKGROUND: Risk factors for impairment in psychosexual development and satisfaction among adult survivors of childhood cancer are poorly understood. The authors compared psychosexual outcomes between survivors and healthy controls, and tested whether at-risk survivors can be identified by 1) treatment neurotoxicity or 2) diagnosis. METHODS: A total of 144 young adult survivors of childhood cancer and 144 matched controls completed questionnaires regarding psychosexual development, sexual satisfaction, and satisfaction with relationship status. Survivors were aged 20 to 40 years and were 5 to 34 years after diagnosis. Using medical chart data, survivors were divided into non-neurotoxic (48 survivors), low-dose (36 survivors), and high-dose (58 survivors) neurotoxic treatment groups. RESULTS: Apart from having fewer lifetime sex partners, survivors did not appear to differ from controls. However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status. Neurotoxic treatment intensity further distinguished between survivors of brain tumors with and without psychosexual impairment. CONCLUSIONS: The intensity of neurotoxic treatment may be a valuable indicator of risk for psychosexual impairment relative to diagnosis alone. Health care providers should assess romantic/sexual problems among survivors at risk and make referrals if needed.
INTRODUCTION
Cancer treatment during childhood can be detrimental for the developing brain and cause lasting neurocognitive impairments. [1] [2] [3] Such impairments can contribute to social difficulties because neurocognitive processes underlie skills needed to navigate complex social interactions. 4, 5 These social difficulties can persist into adulthood, 6 and may cause problems when initiating romantic relationships. Thus, survivors of childhood cancer may face romantic difficulties that are unique to having been diagnosed during childhood (as opposed to adulthood).
Survivors of pediatric brain tumors appear to have the greatest risk of neurocognitive impairments 3 due to tumor location and the direct insult of treatment to the central nervous system (CNS). However, many patients with brain tumors are treated with surgery only, which is an insult to the brain but not necessarily toxic (ie, poisonous). Thus, categorizing risk based on diagnosis may be an oversimplification, because other non-CNS pediatric cancers also are treated with highly neurotoxic agents. Specifically, cranial radiation and (intrathecal/intravenous) methotrexate have been identified as the most toxic risk factors for neurocognitive deficits 7 among survivors of brain tumors or acute lymphoblastic leukemia. 1, 2 Cranial radiation is particularly detrimental and was consistently found to be associated with poor memory, attention, and reading comprehension. [8] [9] [10] [11] [12] It is interesting to note that survivors of acute lymphoblastic leukemia who were treated with both cranial radiation and intrathecal methotrexate demonstrated worse school achievement, 13 intelligence, and attention 9, 14 than survivors treated with intravenous/intrathecal methotrexate only. Hence, there could be cumulative effects, such that increasing numbers of neurotoxic treatments may be associated with increasingly adverse outcomes. Neurocognitive problems have been related to social difficulties, 5, 15 and survivors of brain tumors in particular were found to be less socially competent 16, 17 and less accepted by peers in school. 15 Other survivors have rated their friendships as worse than controls in adulthood, 18 which was associated with worse romantic functioning. 18 Survivors also were less likely to achieve milestones of psychosexual development, such as being less sexually experienced, [19] [20] [21] [22] older at the time of sexual debut, 19, 20, 23 less likely to have children, 20, [24] [25] [26] or reporting problems in sexual functioning. [27] [28] [29] [30] [31] [32] [33] Several studies also found survivors were less likely to marry than siblings/peers, 20, 23, [34] [35] [36] [37] [38] [39] with survivors of brain tumors 20, [34] [35] [36] [37] [38] or those treated with radiation 36,39 least likely to marry. Nevertheless, marriage rates comparable to those of controls also have been reported. [40] [41] [42] [43] [44] [45] Such inconsistent findings may be attributed to heterogeneous samples and treatment with various levels of neurotoxic agents.
It is important to note that achieving developmental milestones does not suggest (dis)satisfaction or survivors' feelings regarding sexual/romantic activities. Relationship status satisfaction (ie, satisfaction with being in a relationship/single) may offer greater insights than marital status alone. Nevertheless, partnered individuals tend to be more satisfied than single individuals in general. 46 Furthermore, the few studies on sexual satisfaction among survivors of childhood cancer either reported lower satisfaction in survivors than controls, 28, 47 no differences, 45 or lower satisfaction only among male, but not female survivors compared with peers. 29 However, identified differences were small (Cohen's d 5 .26) 28 or based on small 47 and unmatched/dissimilar samples (eg, diverse age, sex, or sample size). 28, 29, 47 Therefore, the current study examined whether survivors of childhood cancer reach fewer milestones of psychosexual development, and report lower sexual and relationship status satisfaction than controls (aim 1). We further examined 1) treatment neurotoxicity and 2) diagnosis as potential risk factors for impairment (aim 2). We hypothesized that neurotoxicity would be a more meaningful risk indicator than diagnosis. We expected that survivors treated with more intense neurotoxic treatment would be less equipped to engage in increasingly intimate relationships, while satisfaction also was explored (compared with controls and other survivors).
MATERIALS AND METHODS

Procedure
Survivors of childhood cancer, treated at Nationwide Children's Hospital, were eligible if they were young adults (aged 20-40 years) who were diagnosed with any malignancy between ages 5 to 18 years and were 5 years after diagnosis. Survivors were identified from 2 patient lists: the hospital's cancer registry and long-term followup clinic. Between 2013 and 2015, eligible survivors were mailed a study invitation with a Web link to participate online. Noncompleters were reminded by telephone after 2 weeks. Participants provided informed consent online before completing the survey and were reimbursed for participation. This study was approved by the Institutional Review Boards of Nationwide Children's Hospital and the University of Groningen. Other data from this sample were published previously. 48 
Participants
Survivors
Invitations were mailed to 539 survivors, but 119 had confirmed incorrect contact information (ie, 420 survivors were potentially contacted). Another 186 survivors had incorrect telephone numbers, suggesting addresses also may have been outdated. Therefore, a minimum of 234 survivors received the invitation, 173 initiated the survey (response rate of 74%-41%), and 166 completed it. A total of 22 survivors were excluded due to skipped/ contradictory answers (12 survivors) or being ineligible (10 survivors 
Neurotoxicity Rating
Based on the literature, 13,49-53 guidelines for survivorship care, 3, 7 and input from experts in pediatric oncology, the following treatments were rated as neurotoxic, with a potential permanent impact on neurocognitive functioning: craniospinal radiation (also focal brain, spine, and total body irradiation), intrathecal chemotherapy (with methotrexate, cytarabine, and/or thiotepa), and intravenous chemotherapies that cross the blood-brain barrier (ie, methotrexate, cytarabine, and/or thiotepa, Table 1 ). Dosages were assigned scores of 0 to 3, with higher scores indicating higher neurotoxicity. High-dose cranial radiation (2400 centigrays) was categorized as the most toxic modality directly administered to the CNS (score of 3), and we stratified scores from there. For example, total body irradiation received a score of 1 as it is usually delivered at a dose of 1800 centigrays, which is comparable to low-dose cranial radiation (which also is rated as "1"). Intrathecal and intravenous chemotherapies received maximum scores of 2 because high doses are considered toxic, but not as toxic as high-dose cranial radiation. 7 
Patient-Reported Outcomes
Psychosexual development
Participants reported psychosexual milestones: sexual debut/intercourse (yes/no), age at sexual debut, number of lifetime sex partners, relationship status (single/partnered), and whether they had biological children (yes/no).
Sexual satisfaction
The Global Measure of Sexual Satisfaction 54 provides participants with 5 semantic differentials (eg, good-bad, pleasant-unpleasant, and satisfying-unsatisfying) that build the anchors of a 7-point scale. For example, participants were asked to rate their satisfaction on a continuum from good to bad. "Sex" was referred to as any sexual behavior (including masturbation, to accommodate single/ inexperienced participants). Scores were summed, with higher scores indicating greater sexual satisfaction. Cronbach's alpha (a) was calculated indicating excellent reliability among survivors and controls (a 5 .92/.93).
Relationship status satisfaction
The Satisfaction with Relationship Status Scale 46 assessed satisfaction with either being single or being in a relationship/married. Five items (eg, "How happy are you with your current status?") were answered on a 4-point scale (ranging from "not at all" to "a great extent"), with higher scores indicating greater satisfaction. Reliability was excellent, with a 5 .96/.95 among survivors/controls.
Statistical Analyses
Descriptive statistics were calculated for psychosexual development, sexual satisfaction, and relationship status satisfaction. Survivors were compared with controls using chi-square (v 2 ) and Student t-tests for categorical and continuous outcomes, respectively (aim 1). Subsequently, survivors were grouped by 1) neurotoxicity or 2) diagnosis and compared with one another and controls, using v 
55 Power analyses using G*Power (University of Duesseldorf, Germany) indicated ample power (>.90) to detect even small differences (d 5 .20) between survivors and controls, and sufficient power (.80) for subgroup comparisons.
RESULTS
Survivors and controls did not differ with regard to sexual debut, age at sexual debut, relationship status, or having children (Table 2 ), but survivors reported fewer sex Table 2 ).
Neurotoxicity and Psychosexual Development
Neurotoxic treatment intensity ranged from 0 to 8, but scores were skewed (ie, scores of 6, 7, or 8 were found in 10 survivors). Therefore, scores were aggregated as follows: non-neurotoxic treatment (index of 0; 48 survivors), lowdose neurotoxic treatment (index of 1-2; 36 survivors), and high-dose neurotoxic treatment (index of 3; 58 survivors, corresponding to at least high-dose cranial radiation or combined other treatments, Table 3 ). Note that these subgroups and controls did not differ with regard to sociodemographic background variables (Table 4) . Sexual debut differed across groups (v 2 5 14.84; p 5 .002, Table 4 ) 55 such that the high-dose group was least likely to be sexually experienced (72%) whereas the non-neurotoxic group demonstrated the highest rates of debut (98%), and survivors in the low-dose group (86%) and controls (87%) were similar. The same pattern was observed for relationship status (v 2 5 11.83; p 5 .008), with the lowest rates of being partnered noted among the high-dose group and the highest rates observed among the non-neurotoxic group (51% vs 83%, Table 4 ). 55 Having children also differed (v 2 5 8.519; p 5 .036), but this time the low-dose group was least likely to have children (14% had children) followed by the high-dose group (24%; vs 40% in the non-neurotoxic group and 34% in controls).
Diagnosis and Psychosexual Development
Repeating these analyses stratified by diagnosis yielded similar differences for sexual debut (v 2 Original Article leukemia were least likely to be partnered (46% and 57%, respectively, vs 83%, see Supporting Information Table  1) .
Neurotoxicity, Diagnosis, and Satisfaction
The main effects of neurotoxicity and diagnosis on relationship status satisfaction and sexual satisfaction were tested in separate analyses of variance, before adjusting for milestones of psychosexual development (which differed among groups: sexual debut, relationship status). Neurotoxicity, but not diagnosis, was found to be related to relationship status satisfaction, such that the non-neurotoxic group reported higher satisfaction than the high-dose group (d 5 .64) and controls (d 5 .63, see Supporting Information Table 2 ). Sexual satisfaction appeared to differ by diagnosis (p 5 .045), but between-group comparisons yielded no significant results (see Supporting Information Table 2 ). When adjusting analyses, neither neurotoxicity nor diagnosis was found to be associated with either type of satisfaction. Rather, only relationship status was related to relationship status satisfaction (ie, partnered individuals were more satisfied) and both relationship status and sexual debut (ie, being partnered, sexually experienced) were related to higher sexual satisfaction (see Supporting  Information Table 2 ).
Neurotoxicity, Diagnosis, and Brain Tumors
As outlined, identifying brain tumor survivors as "at risk" might be an oversimplification. Therefore, we explored the role of neurotoxicity among survivors of brain tumors only. Although subsamples were small, survivors of brain tumors who had received any neurotoxic treatments were less likely to achieve milestones of psychosexual development compared with those treated with non-neurotoxic modalities (see Supporting Information Table 3 ).
DISCUSSION
To the authors' knowledge, the current study is the first to demonstrate that a comprehensive index of neurotoxic treatment intensity may be valuable for identifying young adult survivors of childhood cancer who are at risk of impaired psychosexual development. Apart from having fewer sex partners, survivors as a whole did not differ from controls. However, survivors of brain tumors, leukemia, and overall those treated with high-dose neurotoxic modalities reported the lowest rates of achieving milestones of psychosexual development, but satisfaction did not differ consistently. These findings highlight the subjective nature of psychosexual outcomes and provide directions for future research and care. Having fewer lifetime sex partners was the only difference between the entire group of survivors and controls, but this does not suggest that survivors have difficulty attracting a partner. Anyone may choose to have one lifetime sex partner, whereas others prefer more. Supporting this notion, and rather consistent with previous research, 28, 29, 45 sexual satisfaction did not appear to differ between survivors and controls. However, it was surprising that we did not find more differences in psychosexual development, because the few previous studies published to date have indicated problems. 19, 21, 23, 28, 29 Yet again, frequencies of achieving milestones may not capture survivors' lived experiences. Alternatively, the lack of differences might be related to growth/benefit finding, 56 because many survivors experience closer relationships and greater appreciation for life after treatment. 57, 58 Although finding nearly no overall differences between survivors and controls is encouraging, it bears the risk of overlooking vulnerable subgroups. Survivors of brain tumors and generally those treated with high-dose neurotoxic modalities were found to be least likely to be sexually experienced, in a relationship, or have children. We demonstrated that identifying only survivors of brain tumors as having the worst outcomes may be an oversimplification (see Supporting Information Table 3 ), and that any survivor treated with high-dose neurotoxic treatments may be at risk of impaired/delayed psychosexual development (40% in the current study). Previous studies have found specific treatment factors (eg, cranial radiation [8] [9] [10] [11] [12] ) that effectively identify at-risk survivors of brain tumors (ie, omitting those who were treated with surgery only). However, other survivors who received different neurotoxic treatments would not be detected with this approach (eg, 49% of survivors of leukemia and 30% of survivors of lymphoma in the current study). Thus, more comprehensive ratings of neurotoxicity may better distinguish between survivors at risk of psychosexual problems.
It is interesting to note that although some subgroups (ie, survivors of high-dose and low-dose neurotoxic treatment regimens as well as survivors of brain tumors and leukemia) achieved milestones of psychosexual development at lower rates, this did not specifically relate to their sexual and relationship status satisfaction, but satisfaction was rather related to relationship status in general. Unsurprisingly, the non-neurotoxic group reported the highest status satisfaction, with 98% reporting having a partner. Nevertheless, although the high-dose group had the lowest rates of being partnered, their status satisfaction was comparable to that of the low-dose group and controls. Similarly, sexual satisfaction did not appear to differ by neurotoxicity or diagnosis, although the subgroups differed with regard to milestones. All these findings underscore the subjective nature of sexuality, and future studies may focus on self-perceptions/satisfaction in addition to the attainment of milestones.
Previous studies also have acknowledged the importance of treatment intensity in predicting psychosocial outcomes across diagnostic categories. 59, 60 However, these valuable efforts use treatment intensity as a proxy for physical stress/strain and require an extensive knowledge of childhood cancer treatments/protocols. In contrast, our rating focuses specifically on neurotoxic treatments as biological underpinnings that potentially cause neurocognitive impairments and may affect a child's social and psychological development. 5 Although we encountered some problems extracting data from medical charts (eg, missing information), this may prove less burdensome with the increasing use of electronic medical records. In addition, our neurotoxicity rating also may be used as a checklist: If a survivor had treatments that summed to an index 3, she or he could be flagged as being at risk. Nevertheless, more research is needed and other study limitations also should be considered: Although power was adequate and effect sizes often were considerable, the subgroups in the current study were small. As the treatment of childhood cancer is constantly evolving, considering new agents or techniques (eg, proton beam therapy) may be warranted. In addition, age at diagnosis should be considered because cancer treatments may be more detrimental for younger children. 10, 11, 61 We did not find any effect for age (diagnosis before vs after age 13 years), but children aged <5 years at the time of diagnosis were excluded, a group with a high risk of neurocognitive deficits. Last, our premise that neurotoxic treatments cause neurocognitive impairments and social difficulties, 1-3 which cascade into romantic difficulties, 6 remains to be tested prospectively.
To conclude, the current study demonstrated that an index of neurotoxic treatment for childhood cancer could identify survivors who are at risk of worse psychosexual functioning. Additional research is needed to delineate how neurocognitive impairment undermines social outcomes for survivors, as well as other related factors. Given the findings of the current study, health care providers should assess romantic/sexual problems among survivors, especially those who received high-dose neurotoxic treatments. Referrals to psychosocial care could prevent or reduce potential difficulties.
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